España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Novo Nordisk
NVO
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Why is it moving?
Novo Nordisk shares are trading higher after the company reported Q4 financial results and beat its EPS and revenue estimates.
Get Report
Comment
Q4 2024 earnings were released today before the market open
Today's conference call ended over 13 hours ago
Click to view the webcast
Novo Nordisk (NVO) Forecast
News
Earnings
Novo Nordisk (NVO) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Novo Nordisk (NYSE:NVO) Stock
Novo Nordisk Stock (NYSE: NVO)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, February 05, 2025
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Vandana Singh
Novo Nordisk shares are trading higher after ...
Benzinga Newsdesk
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
Vandana Singh
Earnings Scheduled For February 5, 2025
Benzinga Insights
Novo Nordisk Forecasts 2025 Sales Growth Of 1...
Benzinga Newsdesk
Novo Nordisk Q4 2024 GAAP EPS DKK 6.34 Beats ...
Benzinga Newsdesk
Tuesday, February 04, 2025
$100 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today
Benzinga Insights
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside
Surbhi Jain
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Vandana Singh
Monday, February 03, 2025
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Benzinga Insights
Thursday, January 30, 2025
Novo Nordisk Says New Phase III Trial Of Obes...
Benzinga Newsdesk
Novo Nordisk To Begin New Phase III Trial Of ...
Benzinga Newsdesk
Wednesday, January 29, 2025
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Anthony Noto
Tuesday, January 28, 2025
Ozempic Receives FDA Approval To Treat Kidney Disease
Erica Kollmann
FDA Approves Ozempic As The Only GLP-1 RA To ...
Benzinga Newsdesk
How Ozempic And Legal Weed Are Changing What America Eats
Javier Hasse
Monday, January 27, 2025
Market Whales and Their Recent Bets on NVO Options
Benzinga Insights
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Vandana Singh
Friday, January 24, 2025
Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?
Piero Cingari
Customers Bancorp, Twilio, Dana And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Novo Nordisk shares are trading higher after ...
Benzinga Newsdesk
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Vandana Singh
Novo Nordisk Successfully Completes Phase 1b/...
Benzinga Newsdesk
Wednesday, January 22, 2025
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
Vandana Singh
Tuesday, January 21, 2025
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Benzinga Insights
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Benzinga Insights
Sunday, January 19, 2025
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Lekha Gupta
Friday, January 17, 2025
Novo Nordisk Unusual Options Activity
Benzinga Insights
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Vandana Singh
Novo Nordisk shares are trading lower after O...
Benzinga Newsdesk
Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss
Vandana Singh
'Ozempic Is In The Next Round Of Medicare Dru...
Benzinga Newsdesk
Novo Nordisk Reveals Headline Results From ST...
Benzinga Newsdesk
Thursday, January 16, 2025
U.S. FDA Chief Califf Says Current Regulation...
Benzinga Newsdesk
Tuesday, January 14, 2025
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Eli Lilly Tumbles: What's Driving Markets Tuesday? (CORRECTED)
Piero Cingari
Novo Nordisk shares are trading lower in symp...
Benzinga Newsdesk
Thursday, January 09, 2025
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower (UPDATED)
Avi Kapoor
Wednesday, January 08, 2025
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Vandana Singh
UBS Upgrades Novo Nordisk to Buy
Benzinga Newsdesk
Novo Nordisk shares are trading higher after ...
Benzinga Newsdesk
Novo Nordisk And Valo Health Entered Into An ...
Benzinga Newsdesk
Tuesday, January 07, 2025
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Vandana Singh
Monday, January 06, 2025
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Vandana Singh
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Vandana Singh
Thursday, January 02, 2025
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Benzinga Insights
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Vandana Singh
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Vandana Singh
Monday, December 30, 2024
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Benzinga Insights
Saturday, December 28, 2024
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
Anan Ashraf
Friday, December 27, 2024
Behind the Scenes of Novo Nordisk's Latest Options Trends
Benzinga Insights
Show More